Efficacy and safety of Uro-vaxom treatment for patients with recurrent cystitis: open multicentre study
Abstract number: 1733_286
Ha U-S., Chang S-G.C., Park H.K., Yoon S.J., Cho Y-H.
Objectives: To investigate the efficacy and safety of the immunotherapeutic Uro-vaxom in uncomplicated recurrent cystitis in female patients only.
Methods: Adult female patients could enroll in this multicentre, open-label study if they had acute cystitis at the enrollment visit and positive results of urine culture (≥103 CFU/mL). Patients were treated for 3 months with one capsule daily of Uro-vaxom after antibiotic therapy and observed for further 3 months. Primary efficacy criteria were cystitis recurrence rates over 6 months, distribution of cystitis and proportion of patients of cystitis.
Results: A total of 50 patients were evaluated. During the 6-month trial the number of recurrences from cystitis was significantly reduced in comparison with the 6-month pretrial period (on the average 0.64 as compared to 3.0 recurrences, p < 0.001). The case for the incidence of frequency, urgency and dysuria was remained low until the end of the trial. Uro-vaxom was well tolerated: side-effects were mentioned in 8% of the 50 patients, in the absence of case leading to treatment withdrawal.
Conclusions: Uro-vaxom significantly reduced the incidence of cystitis during the 6 months of the study including 3 months of treatment. These results demonstrate that Uro-vaxom is a valuable product for the prophylaxis of recurrent cystitis.
|Session name:||European Society of Clinical Microbiology and Infectious Diseases|
|Location:||ICC, Munich, Germany|
|Back to top|